Original Research and the Latest News

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

by | October 26, 2025 | Business, Data Analytics, Industry Trends, Market Scan, New Technology, Probability of Success | 0 Comments

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

by | October 16, 2025 | New Technology, Probability of Success | 0 Comments

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

by | October 9, 2025 | New Technology, Probability of Success | 0 Comments

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

We’re Back!

Oct 27, 2017 |

Ozmosi has been on a purpose-driven hiatus peppered with innovation, development and growth. In less than one year, we have...

Recent Tweets

Ozmosi Follow

BioPharma/Biotech Intel. Daily $XBI $XPH Market Movers Database: https://t.co/IBOqbSoYuc Clinical trial tools: https://t.co/A77u9Q84Dc https://t.co/AQERg9nHrb

OzmosiHealth
ozmosihealth Ozmosi @ozmosihealth ·
15 Dec

$RLAY Relay Therapeutics presented P1 Breast Cancer results on 2025-12-12 for Zovegalisib

More Info: https://pryzm.ozmosi.com/product/25143

Reply on Twitter 2000675104414453764 Retweet on Twitter 2000675104414453764 Like on Twitter 2000675104414453764 1 Twitter 2000675104414453764
ozmosihealth Ozmosi @ozmosihealth ·
15 Dec

$MLYS Mineralys Therapeutics presented P3 Resistant Hypertension results on 2025-12-12 for Lorundrostat

More Info: https://pryzm.ozmosi.com/product/23111

Reply on Twitter 2000675100429803674 Retweet on Twitter 2000675100429803674 Like on Twitter 2000675100429803674 1 Twitter 2000675100429803674
ozmosihealth Ozmosi @ozmosihealth ·
15 Dec

$LLY Eli Lilly presented P3 Breast Cancer results on 2025-12-12 for Imlunestrant

More Info: https://pryzm.ozmosi.com/product/21349

Reply on Twitter 2000675095996481785 Retweet on Twitter 2000675095996481785 Like on Twitter 2000675095996481785 Twitter 2000675095996481785
ozmosihealth Ozmosi @ozmosihealth ·
15 Dec

$AB -0.32% today as AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

More Info: https://pryzm.ozmosi.com/product/25100

Reply on Twitter 2000674695046222123 Retweet on Twitter 2000674695046222123 Like on Twitter 2000674695046222123 Twitter 2000674695046222123
Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

Get in Touch

info@ozmosi.com
(732) 701-7807

600 Warren Ave,
Spring Lake, NJ 07762